Buckwheat may be beneficial for managing diabetesNovember 17, 2003
Researchers in Canada have found new evidence that buckwheat, a grain used in making pancakes and soba noodles, may be beneficial in the management of diabetes. In a controlled study, they showed that extracts of the seed lowered blood glucose levels by 12 percent to 19 percent when fed to diabetic rats. The report comes at a particularly appropriate time since November is National Diabetes Awareness Month. The study may lead to new uses of the grain as a dietary supplement or functional food to help people with diabetes and others with conditions involving elevated glucose, the researchers claim. Their findings will appear in the Dec. 3 issue of the Journal of Agricultural and Food Chemistry, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society.
"With diabetes on the rise, incorporation of buckwheat into the diet could help provide a safe, easy and inexpensive way to lower glucose levels and reduce the risk of complications associated with the disease, including heart, nerve and kidney problems," says study leader Carla G. Taylor, Ph.D., an associate professor in the Department of Human Nutritional Sciences at the University of Manitoba in Canada. "Buckwheat won't cure diabetes, but we'd like to evaluate its inclusion in food products as a management aid."
Until similar studies are done on humans with diabetes, no one knows exactly how much buckwheat -- in flour or extract form -- must be eaten in order to obtain a beneficial effect on glucose levels, Taylor says. Further studies are needed, she adds.
To analyze the effect of buckwheat on elevated blood glucose levels, the researchers studied a group of rats (approximately 40) with chemically-induced diabetes. The rat models represented Type 1 diabetes (insulin-dependent), which is characterized by a lack of insulin, a hormone needed by cells to utilize glucose properly. Under controlled conditions, the rats were given a single dose of either buckwheat extract or a placebo and their glucose levels were subsequently measured.
Blood glucose concentrations were reduced by 12 percent to 19 percent in the rats that were fed the extract, while no glucose reduction was observed in the rats that received the placebo, demonstrating that buckwheat extract can lower glucose levels in diabetic animals after a meal, the researchers say.
Based on studies by others, the active component in buckwheat responsible for lowering blood glucose appears to be chiro-inositol, they say. The compound, which is relatively high in buckwheat and rarely found in other foods, has been previously shown in animal and human studies to play a significant role in glucose metabolism and cell signaling. Researchers do not know exactly how it works, but preliminary evidence suggest that it may make the cells more sensitive to insulin or may act as an insulin mimic.
There could be other compounds in buckwheat that reduce glucose levels, but these were not identified in this study, says co-investigator Roman Przybylski, Ph.D.
Although the rats used in this study were models for Type 1 diabetes, the researchers predict that buckwheat will have a similar glucose-lowering effect when given to rat models of Type 2 diabetes, which they plan to test next. Also known as non-insulin dependent diabetes, Type 2 is the most common form in people and is characterized by the inability of cells to respond properly to insulin.
Przybylski is currently collaborating with Kade Research Ltd., a Canadian-based company involved in research and development of new buckwheat varieties that contain much higher amounts of chiro-inositol for food applications.
-- Mark T. Sampson
The online version of the research paper cited above was initially published Nov. 1 on the journal's Web site. Journalists can arrange access to this site by sending an e-mail to firstname.lastname@example.org or calling the contact person for this release.
American Chemical Society
Related Diabetes Articles from Brightsurf:
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.
Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.
Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.
Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).
Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.
Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Read More: Diabetes News and Diabetes Current Events